Rocket Doctor AI closes debenture placement
Analysis based on 9 articles · First reported Jul 28, 2026 · Last updated Aug 06, 2026
The successful closing of the first tranche provides Rocket Doctor AI, Inc. with additional capital to fund its US expansion, potentially supporting its growth and liquidity. The 12% interest rate and conversion features may dilute existing shareholders if converted, but the capital infusion is generally positive for the company's near-term operations.
Rocket Doctor AI, Inc. Inc., a Vancouver-based healthcare AI company, announced on July 28, 2026 a proposed non-brokered private placement of unsecured convertible debentures for aggregate gross proceeds of up to CAD $2,000,000. On August 6, 2026, the company closed the first tranche of the offering, raising CAD $2,269,000. The debentures bear interest at 12% per annum, mature in 12 months, and are convertible into units at CAD $0.70 per unit, each unit consisting of one common share and one warrant exercisable at CAD $0.75 for 12 months. Proceeds will be used for working capital and general administrative expenses, primarily for US growth plans. The company paid CAD $86,730 in finders fees. The securities are subject to a four-month hold period and were not registered under US securities laws.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard